EDMONTON, Alberta, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce it has filed an additional 17 provisional patent applications (the “Patent Applications”) with the United States Patent and Trademark Office (the “USPTO”). These applications cover inventions related to novel and improved methods and systems of consuming cannabis extracts and cannabis-infused products, in particular for medicinal cannabis consumers. These filings bring the total number of patent applications filed by the Company in 2018 and 2019 to 60, and mark the expansion of the Company’s intellectual property in the consumer and medical sectors of the cannabis and hemp industries.

Further Details: Provisional Patent Applications for Cannabinoid Consumption Products and Devices

In order to meet the growing consumer demand for safe cannabinoid-infused products and devices with an improved variety of delivery methods, the Patent Applications relate to novel devices capable of accurately monitoring cannabis consumption, providing relief from cannabis-induced side effects, and delivering cannabinoid extracts via alternate pathways (e.g. nasal, oral mucosal, transdermal, etc.).

Several of these inventions provide novel solutions which may reduce harm and discomfort associated with existing methods of consuming cannabis products, specifically for medicinal cannabis patients. For example, cannabis has traditionally been consumed by smoking, which has negative effects on the respiratory system. Alternatively, cannabis is often consumed orally, such as through the ingestion of cannabis ‘edibles’, which are associated with a delayed onset and bioavailability, as well as difficulties with controlling dosage. These inventions could eliminate or reduce the risks associated with cannabinoid dosage and delivery to create safer, standardized cannabinoid-infused products. 

The Patent Applications also disclose methods of improving the experience of cannabis consumption for medicinal cannabis patients and consumers. These include methods for allowing cannabis consumers to share experiences over social media, testing methodologies for determining consumer preferences for product selection, and monitoring user biometrics to suggest consumption schedules.

The Patent Applications were first filed in the USPTO to create a priority date and allow for future filings in other selected jurisdictions, as appropriate, including Canada.

Dr. Steven Splinter, Founder and CTO of Radient, stated: “We are excited to leverage our considerable experience, research and expertise in the extraction and formulation of natural products in order to enable the development of improved cannabinoid delivery methods and devices, specifically for medicinal cannabis patients. Cannabis is becoming increasingly accepted by medical professionals as an effective treatment for a variety of illnesses and disorders. As governments all over the world continue to ease restrictions surrounding science and research-backed cannabinoid-based medicines and treatments, there is a strong need for safe, standardized products that can be trusted by the healthcare industry, and more importantly, by patients consuming cannabis products for medical purposes. By looking ahead and envisioning how our unique, high-grade extracts may be used by consumers globally, Radient is establishing a commanding and sustainable advantage over competing technologies and competitors.”

About Radient
Radient Technologies provides industrial-scale manufacturing solutions for premium natural ingredients and products. Utilizing its patented MAP™ extraction technology, Radient delivers superior customer outcomes in terms of ingredient purity, yield, and cost, and serves global market leaders in industries such as foods & beverages, nutraceuticals, pharmaceuticals, cosmetics, and personal care. Since 2016, Radient has expanded its offerings to enter the cannabinoids market, using its MAP™ platform to provide premium ingredients that contain a full range of cannabinoid and terpene profiles. Please visit www.radientinc.com  for more information.  

SOURCE: Radient Technologies Inc.

Denis Taschuk, Chief Executive Officer, dtaschuk@radientinc.com,
(780) 465-1318;  

Mike Cabigon, Chief Operating Officer, mcabigon@radientinc.com,
(780) 465-1318 

Caitlin Cheadle, Director of Communications, ccheadle@radientinc.com

Forward Looking Information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations; the Company’s ability to obtain approval for the Patent Applications; the impact of the inventions to the Company’s business; the Company’s ability to file similar Patent Applications in other jurisdictions; the Company’s ability to grow its business in the cannabis sector and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.